At a glance
ClinicalIndex Comparison RecordN/ACompleted· 170 enrolled
Drug / intervention
Assessment of PDL1 expressionother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Epidemiologic Multicenter Prospective Study in Advanced NSCLC Patients With PDL1 Expression : Evaluation of Clinical and Pathological Characteristics of PDL1 High Expression Patients Compared to Patients With a Weak or no Expression of PDL1.
In Brief
A clinical study evaluating Assessment of PDL1 expression for Lung Cancer. Completed, enrolled 170 participants across 13 sites.
Detailed Summary
Epidemiologic multicenter prospective study in advanced NSCLC patients with PDL1 expression : evaluation of clinical and pathological characteristics of PDL1 high expression patients compared to patients with a weak or no expression of PDL1.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesFrance
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedMay 2016
Enrollment StartJul 2016
Primary CompletionApr 2020
TodayJul 2026
First PostedMay 30, 2016
Enrollment StartJul 21, 2016
Primary CompletionApr 6, 2020
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 10.1 years ago
Interventions
Assessment of PDL1 expressionother
Intervention : 2 biopsy slides will be analyzed in central laboratory.